Management of Atrial Fibrillation

Stroke Prevention

The American College of Cardiology recommends oral anticoagulation for all atrial fibrillation patients with stroke risk factors to prevent thromboembolism 2
Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban are preferred over vitamin K antagonists in eligible patients due to lower risk of intracranial hemorrhage 2
For patients on warfarin, the European Society of Cardiology recommends maintaining INR between 2.0-3.0 with weekly monitoring during initiation and monthly when stable 2
Patients with AF lasting >48 hours or of unknown duration require at least 3-4 weeks of anticoagulation before and after cardioversion 3, 2
The American Heart Association recommends transesophageal echocardiography with short-term anticoagulation followed by early cardioversion as an appropriate alternative to delayed cardioversion with pre- and post-anticoagulation 1

The European Society of Cardiology recommends beta-blockers, diltiazem, verapamil as first-line medications for rate control in patients with preserved ejection fraction (LVEF >40%) 2
Beta-blockers and/or digoxin are recommended for patients with reduced ejection fraction (LVEF ≤40%) 2
The American College of Cardiology recommends specific drugs such as atenolol, metoprolol, diltiazem, and verapamil for their demonstrated efficacy in rate control during exercise and rest 1
Digoxin is only effective for rate control at rest and should only be used as a second-line agent 1, 2
A combination of digoxin with a beta-blocker or calcium channel antagonist may be more effective for controlling heart rate both at rest and during exercise 2
For patients with obstructive pulmonary disease, the European Respiratory Society recommends non-dihydropyridine calcium channel antagonists (diltiazem or verapamil) for rate control 4
Beta-1 selective blockers in small doses may be considered as an alternative in patients with obstructive pulmonary disease 4

The American Heart Association recommends rhythm control when based on special considerations such as patient symptoms, exercise tolerance, and patient preference 1
For acute cardioversion to achieve sinus rhythm, both direct-current cardioversion and pharmacological conversion are appropriate options 1
Electrical cardioversion is recommended for patients with AF causing hemodynamic instability 2
For patients converted to sinus rhythm, most should not be placed on rhythm maintenance therapy since the risks outweigh the benefits 1
In selected patients whose quality of life is compromised by AF, recommended agents for rhythm maintenance include amiodarone, disopyramide, propafenone, and sotalol 1
Catheter ablation should be considered when antiarrhythmic medications fail to control symptoms 2

The European Society of Cardiology recommends restoration of sinus rhythm by direct current cardioversion or pharmacological cardioversion in patients with HCM presenting with recent-onset AF 5
Oral anticoagulation therapy (INR 2.0–3.0) is recommended in patients with HCM who develop AF unless contraindicated 5
Amiodarone (or alternatively, disopyramide plus β-blocker) should be considered to achieve rhythm control and maintain sinus rhythm 5

The European Respiratory Society recommends correction of hypoxemia and acidosis as initial management for patients who develop AF during acute pulmonary illness 4
Direct current cardioversion should be attempted in patients with pulmonary disease who become hemodynamically unstable due to AF 4
Theophylline and β-adrenergic agonist agents are not recommended in patients with bronchospastic lung disease who develop AF 4

Underdosing anticoagulation or inappropriate discontinuation increases stroke risk 2
Using digoxin as the sole agent for rate control in paroxysmal AF is ineffective 1, 2
Failing to continue anticoagulation after cardioversion in patients with stroke risk factors 2
Attempting cardioversion without appropriate anticoagulation in patients with AF lasting more than 48 hours 3
Failing to identify and treat reversible causes of atrial fibrillation, such as thyroid dysfunction or electrolyte abnormalities 3